(Q33579892)

English

Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

object named as

Brian Bot

3

0 references

Daniel J. Sargent

object named as

Daniel J Sargent

9

0 references

Ronald P DeMatteo

4

object named as

Ronald P DeMatteo

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

5

object named as

Edith A Perez

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

author name string

Shauna L Hillman

1

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Sumithra J Mandrekar

2

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Karla V Ballman

6

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Heidi Nelson

7

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Jan C Buckner

8

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

language of work or name

0 references

publication date

17 May 2010

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

18

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

3002-3007

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2903334

21 June 2018

Dealing with a deluge of data: an assessment of adverse event data on North Central Cancer Treatment Group trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2903334

21 June 2018

The reliability of medical record review for estimating adverse event rates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2903334

21 June 2018

Nonspecific medication side effects and the nocebo phenomenon

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2903334

21 June 2018

Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2903334

21 June 2018

Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2903334

31 October 2018

Factors Affecting Workload of Cancer Clinical Trials: Results of a Multicenter Study of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20479400

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of physicians' attitudes on reporting adverse drug events: a case-control study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20479400

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The placebo effect in healthy volunteers: influence of experimental conditions on the adverse events profile during phase I studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/20479400

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2009.27.4282

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33579892&oldid=1653182095"